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1992.-This in vitro study evaluates the effect of aluminum (A13+) on osteocalcin, a small protein that is produced by the osteoblast. After stimulation with various doses of 1,25dihydroxyvitamin D3 [1, 25(OH) ,D,; lo-l1 to 10eg M], osteocalcin was consistently lower in the culture medium of ROS 17/2 osteoblastic cells conditioned with 5 PM A13+-saturated transferrin (AlTR) than in apotransferrin (ApoTR)-treated controls. In a second experiment, cultures were conditioned with various doses of AlTR or ApoTR (1.6-8.0 PM) and stimulated with 10Bg M 1,25(OH),D,. High doses of AlTR (4.8-8.0 PM) resulted in lower medium and unchanged intracellular content of osteocaltin than treatment with equal amounts of ApoTR. However, in the same experiment, lower doses of AlTR or ApoTR (1.6 and 3.2 PM) yielded different results, i.e., increased medium and intracellular contents of osteocalcin in the A13+-treated cells. Expression of osteocalcin mRNA was not altered in cultures conditioned with low (1.6 PM) or high (8.0 PM) concentrations of AlTR or ApoTR. Similarly, no effect of A13+ was observed on total protein content, the rate of total protein synthesis, and the degradation of secreted osteocalcin in cultures conditioned with various doses of AlTR or ApoTR. These findings suggest that AlTR affects osteocalcin synthesis in a specific manner, without concomitant effects on the rate of total protein synthesis or on the rate of degradation of osteocalcin. This effect is dose dependent, i.e., low doses of AlTR stimulate and high doses suppress osteocalcin synthesis and/or secretion, and it appears to be posttranscriptional, since the expression of osteocalcin mRNA is not affected. calcitriol; osteocalcin messenger ribonucleic acid END-STAGE RENAL DISEASE patientson dialysis therapy are prone to aluminum (A13+) overload, a condition associated with high morbidity and mortality (33) . Even though the use of non-A13+-containing phosphorus binders should eventually reduce the frequency of A13+ accumulation, the ubiquitous prevalence of this element results in persistence of A13+ overload in a significant number of patients on dialysis (14) .
Aluminum accumulation in bone is associated with characteristic histological and clinical findings. Experimental and clinical studies have suggested mechanisms by which A13+ may affect the bone tissue. Effects of A13+ on calciotropic hormone metabolism, bone histopathology, bone cell function, and the physical-chemical interaction of minerals with the organic matrix of bone have been described (for review, see Ref. 6 ). Another study concluded that A13+ represents an epiphenomenon of the osteomalacic state (32).
Osteocalcin, also known as BGP, is a small protein (5,800 relative mol wt) containing two to three residues of y-carboxyglutamic acid. It is produced by the osteoblast and is found in the bone matrix in quantities comparable on a molar ratio to tropocollagen (8) and also in the circulation in nanomolar concentrations (30). The role of osteocalcin in bone metabolism is not established, but important physiological function(s) of this protein are suggested by in vivo studies correlating the circulating levels of osteocalcin with bone turnover and/or formation (5, 15) and by in vitro studies demonstrating the paracrine effects of this protein on bone mar row osteoclast precursors (16) as well as modulation of its synthesis by 1,25dihydroxyvitamin D3 [ 1,25(OH)2-D3] (28) and growth factors (23).
Demonstration of a direct effect of A13+ on osteocalcin production by the osteoblasts would offer support to the hypothesis that this element exerts important direct effects on bone cells.
MATERIALSAND METHODS
Rat osteosarcoma cells ROS 17/2 and a rat osteocalcin-specific cDNA clone were kindly provided by Dr. Paul Price (University of California, San Diego, CA). F-12 Coon's modification powder medium, unsaturated human transferrin, sodium EDTA, and aluminum chloride were purchased from Sigma Chemical (St. Louis, MO). Fetal calf serum (FCS) was obtained from HyClone Laboratories (Logan, UT), and penicillin, streptomycin, and amphotericin B (PSA) were from GIBCO (Grand Island, NY). The disodium form of nitrilotriacetic acid (NTA) was obtained from ICN Biochemicals (Cleveland, OH), guanidinium thiocyanate was from ICA (Costa Mesa, CA), [35S] -methionine (sp act X,000 Ci/mmol) was from New England Nuclear (Boston, MA), and 3a70B scintillation cocktail was from Research Products International (Mount Prospect, IL). Goat anti-rat osteocalcin antiserum was purchased from Biomedical Technologies (Stoughton, MA). Donkey anti-goat immunoglobulin (Ig) G antiserum and normal goat serum were purchased from Pel-Freez Biologicals (Rogers, AZ).
Determination
of aluminum.
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EFFECTS OF ALUMINUM ON OSTEOCALCIN NaHC03, and 1.2 mM A13+-NTA (for AlTR) or NTA (for Apo-TR) in 5 mM tris(hydroxymethyl)aminomethane (Tris) l HCl (pH 7.4) were incubated for 2 h at 25°C and then dialyzed four times for 6-10 h each time against 40 vol of 5 mM Tris buffer (pH 7.4) at 4°C using EDTA-washed dialysis bags (10,000 mol wt cutoff). The A13+ concentration of the dialyzed solutions in several preparations was 109-119 PM for AlTR and 0.2 PM for ApoTR. If it is assumed that transferrin can bind two A13+ equivalents per mole (18)) these concentrations of A13+ amount to 52-58% (AlTR) and 0.1% (ApoTR) saturation of the protein.
The solutions were sterilized with 0.2-pm disposable filters, stored at 4"C, and used within 3 wk.
Cell culture conditions and protocols. ROS 1712 cells were maintained in F-12 Coon's modification medium supplemented with FCS and 0.5% PSA, at 37°C in a humidified atmosphere of 95% air-5% CO, (22). The medium was changed every 2 days, and cells were subcultured once per week. In keeping with previous reports (28), addition of l,25(OH)2D3 (lo-l1 to 10B8 M) to confluent cultures stimulated a severalfold rise of medium osteocalcin. This effect was dose dependent and biphasic with maximal stimulation at 10Bg M l,25(OH)2D3. It started 6 h after the addition of the hormone and continued for an additional 12 h.
To study the effect of A13+ on osteocalcin synthesis, cells were exposed to AlTR or ApoTR for two consecutive growth cycles, since preliminary experiments conducted with one single growth cycle resulted in a statistically nonsignificant trend toward the findings presented in this paper. Cells were seeded at low density (1.5 x lo* cells/cm2) in 250-ml flasks and cultured with medium containing 10% FCS and varying amounts of AlTR or ApoTR (1.6-8.0 PM) or vehicle (5 mM Tris, pH 7.4). At confluence the cells were resuspended by trypsin-EDTA digestion, reseeded at 50% density (4 x IO* cells/cm2) in wells, and grown to confluence in medium with the same composition, at which time they were ready for studies on osteocalcin production. The medium was changed to 2% FCS with the same concentrations of AlTR or ApoTR as above, and osteocalcin production was stimulated for 48 h by adding 1,25(OH),D, or vehicle (5 ~1 ethanol) to the medium twice (i.e., every 24 h). Aliquots of medium were taken 48 h after the first addition of l,25(OH),D3 or vehicle for measurement of secreted osteocaltin. To determine the intracellular concentration of osteocalcin, the cells from each well were harvested by trypsin-EDTA digestion, washed with phosphate-buffered saline (PBS), resuspended in 50 ~1 of 6 M guanidine hydrochloride in 0.1 M Tris (pH 8.0), and lysed with repeated freezing and thawing. All samples were stored at -80°C (28).
To study the rate of total protein synthesis, the same protocol as for osteocalcin synthesis was used, with the exception that 2 h before the end of the experiment 25-50 &i [35S]methionine (sp act >l,OOO Ci/mmol) were added to each culture.
To study the effect of A13+ on osteocalcin degradation, the same protocol as for osteocalcin synthesis was followed, with the exception that only 1.6 and 8.0 PM AlTR or ApoTR were used. At confluence, after a 48-h incubation with 2% FCS, AlTR or ApoTR, and l,25(OH)2D3 or vehicle, the culture media were harvested, aliquoted in 400 ~1 fractions, spiked with 50-400 rig/ml rat osteocalcin or vehicle (10 ~15 mM Tris l HCl, pH 7.4), and incubated for 24 h at 37°C in a humidified atmosphere of 5% C02. The aliquots were then assayed for osteocalcin content by radioimmunoassay.
To study the effect of A13+ on the expression of osteocalcin mRNA, a protocol analogous to the one for osteocalcin synthesis was followed except that only 1.6 and 8.0 PM AlTR or ApoTR were used and that, after having reached confluence in 250-ml flasks, the cells were subcultured in 176 cm2 plates for the final part of the. experiment. Also, the final incubation with l,25(OH)2D3 or vehicle was carried out for only 6 h. This incubation time was selected because we found medium osteocalcin concentration to start rising 6 h after stimulation with 1,25-(OH)2D3 (see above); mRNA expression and translation can be expected before this time. At the end of the experiment, the medium was discarded and the cells used for the determination of osteocalcin mRNA.
Determination
of osteocalcin, total protein content, and rate of total protein synthesis. Osteocalcin concentration in culture medium and cultured cell cytosol was measured by nonequilibrium radioimmunoassay (7)) using goat anti-rat osteocalcin antiserum at a final dilution of 1:6,000. Standards and radiolabeled tracer were prepared with rat bone osteocalcin purified in our laboratory (4). The tracer was radioiodinated by the lactoperoxidase method (7). The assay was terminated by second antibody precipitation with donkey anti-goat IgG antiserum. The detection limit was 0.4 rig/ml. The intra-assay and interassay variations were 7 and 9%, respectively. Preliminary studies from our laboratory had shown that the addition of up to 40 yM AlTR or ApoTR to samples of cell culture medium did not interfere with the performance of the assay. We also established that the antiserum used for this assay has equal affinity for carboxylated and decarboxylated rat osteocalcins prepared in our laboratory following the method of Poser and Price (27) . BGP content of medium and cells is expressed as nanogram of BGP per milligram of cell protein.
Total protein content of the cell monolayers was determined in parallel cultures by the method of Lowry et al. (13) . For this purpose the cells were resuspended by trypsin-EDTA digestion, washed once with PBS, and lysed by sonication.
The rate of total protein synthesis was assessed by measuring the incorporation of radiolabeled amino acids into newly synthesized proteins. After incubation of the cultures with [35S]-methionine, the cell monolayers were rinsed with PBS, collected by scraping, and homogenized by sonication. The homogenates were mixed with 24% trichloracetic acid, and the proteins were precipitated by centrifugation. The pellets were resuspended with 10% sodium dodecyl sulfate, mixed with aqueous scintillation cocktail, and counted on an LKB liquid scintillation counter (Wallac, Finland).
Northern analysis. Osteocalcin mRNA was determined with a modified method originally described by Chirgwin et al. (3) . The cells were rinsed with PBS and collected by scraping in 1.5 ml of guanidinium isothiocyanate. After homogenization with a Polytron PTA 10 S (Brinkmann, Westbury, NY), the samples were centrifuged at 10,000 revolutions/min (rpm) for 10 min at 10°C and total RNA was isolated from the supernatant by ultracentrifugation at 30,000 revolutions/min (rpm) for 18 h at 10°C with a Beckman SWGO-TI rotor (Fullerton, CA) using a selfforming cesium chloride gradient (5.7 M CsCl, 0.1 M sodium EDTA, pH 7.0). Recovered total RNA was quantitated by spectrophotometry and electrophoresed on 1% agarose gels in 20 mM 3-(N-morpholino)propanesulfonic acid buffer. Ethidium bromide was included in the samples to determine equal quantities of RNA. After sequential washing, RNA was blotted onto nitrocellulose paper. mRNA levels were determined using the rat osteocalcin cDNA clone (25) and a rat @actin clone (24). The restriction fragment containing the DNA inserts was labeled with [ar-32P]CTP (>3,000 Ci/mmol) by nick translation to a specific activity of at least lo8 counts l min-l (cpm) l p8-l. The nitrocellulose transfers were prehybridized for 20 min at 42°C and hybridized overnight for 12-16 h at the same temperature with lo6 cpm DNA probe/ml hybridization solution.-Filters were washed in 2~ and IX saline-sodium citrate at 65°C. Autoradiography was performed at -70°C with Kodak XAR-5 film and Du Pont Cronex Lightning Plus screens. mRNA levels were quantitated by scanning densitometry.
Statistics. Cultures were run in duplicate in experiments on osteocalcin mRNA and in quadruplicate for the other studies. 
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Each experiment was repeated at least twice. Results are given as means t SE. Statistical analysis was performed using multiple analysis of variance and two-tailed paired statistics. All computations were performed using the SPSS-PC software package (SPSS, Chicago, IL) on an IBM PC-AT computer. (Fig. 2) . In keeping with the results in Fig. 1 with the same doses of AlTR or ApoTR, but treated with vehicle instead of l,25(OH)2DS, did not display significant differences in osteocalcin secretion. In addition, A13+ had no effect on degradation of osteocalcin. Incubation of known amounts of purified rat osteocalcin in conditioned media from cultures treated with 1.6 and 8.0 PM AlTR or ApoTR and with 10eg M l,25(OH)2D3 or vehicle resulted in complete recovery of the added protein, with no difference observed between the experimental groups. Effect of AZ3+ on intraceZZuZar osteocalcin. Intracellular osteocalcin content was measured in the same cultures used for determination of osteocalcin secretion into the medium (see above). After l,25(OH)2D3 stimulation, cy- was added to cultures twice at 24-h intervals, and intracellular osteocalcin was measured 48 h after first addition. Osteocalcin is expressed in ng/mg total cell protein. Each value is average of 4 determinations. Experiment was repeated 3 times with similar results.
* P e 0.01. resulted in a remarkable increase in the expression of osteocalcin mRNA of both the AlTR-and ApoTRtreated cultures. Expression of osteocalcin mRNA was not different between ApoTR-and AlTR-treated cultures.
DISCUSSION
The present findings are in agreement with results by others, demonstrating that A13+ may affect specialized functions of bone cells. The published observations of an effect of A13+ on alkaline phosphatase activity in neonatal rat calvaria (12) and collagen synthesis in primary cultures of osteoblasts (11) are further expanded by the present finding that Al 3+ does affect 1,25(0H)2D3-stimulated osteocalcin synthesis in cultures of ROS 17/2 osteoblastic cells.
The mode of delivery of A13+ to the cultures is of great relevance. At physiological pH, inorganic A13+ and the A13+ salts of organic acids may not reliably deliver this element to the cells because of their strong tendency to hydrolyze and precipitate into large colloidal complexes (17). Use of these chemical forms of A13+ may therefore result in erratic delivery of A13+ to the cultures and in less than optimal experimental conditions. Recent evidence indicates that transferrin is the major carrier of A13+ in the circulation (18). Mladenovic (20) and Abreo et al. (1) have described a suppressive effect of A13+ on the proliferation and differentiation of erythrocyte precursors and have emphasized the importance of transferrin for these effects to occur. Also, the detailed studies of Kasai et al. (10) in UMR-106 cells have shown that these osteoblastlike cells have specific receptors for transferrin. This protein may therefore be the major carrier of A13+ into bone cells and was used in our studies.
The doses of transferrin used in our experiments (1.6-8.0 PM) are not supraphysiological, and the concentrations of A13+ used (1.8-8.8 PM, i.e., 48-238 pg/l) are comparable to those detected in the serum of dialyzed patients (33). Therefore the observed results might be relevant for uremic patients.
The chosen low doses of AlTR resulted in increased intracellular and medium osteocalcin, whereas high doses were associated with apparently normal intracellular and decreased medium content of the protein. These results are not affected by degradation of secreted osteocalcin, since we found that incubation of osteocalcin in conditioned media from cultures treated with AlTR or ApoTR and 1,25( OH)2D3 or vehicle resulted in complete protein recovery. Also, the effect of A13+ on osteocalcin production appears to be selective, since AlTR-and ApoTRconditioned cultures displayed similar total protein content and rate of protein synthesis. Thus our findings are more likely to reflect altered synthesis and/or secretion of osteocalcin in A13+-treated cells.
In rats, A13+ affects the expression of the 1,25(OH)2D3 receptor and the response of several tissues to exogenous 1,25(OH) 2D3 (19) . Similarly, abnormal production of osteocalcin by osteoblastic cells could result from a direct effect of A13+ on the expression of the osteocalcin gene or from an indirect effect via alterations of the response to 1,25(OH)2D3. However, in our cell system, A13+ did not interfere with the steady-state levels of osteocalcin mRNA, regardless of presence or absence of 1,25(OH)2D3 in the medium. Our findings do not allow categorically exclusion of simultaneous and consensual effects (either stimulatory or suppressive) of A13+ on the 1,25(OH)*D3-induced transcription and on the degradation of osteocaltin mRNA, resulting in unchanged steady-state levels of the messenger. However, this possibility is unlikely and the most obvious interpretation of our findings is that the effects of AP+ on the synthesis of osteocalcin are either translational and/or related to any of the posttranslational events. Posttranscriptional events appear to be responsible for the stimulatory effect of low doses of AP+ on the synthesis of osteocalcin. With high doses of A13+, the low medium osteocalcin and relatively larger amounts of the protein inside the cell could be explained by alterations in processing and/or secretion of the protein.
Osteocalcin is generated as a preproprotein with cleavage to proosteocalcin at the time of incorporation into the endoplasmic reticulum, and to mature osteocalcin after vitamin K-dependent y-carboxylation of two to three glutamic acid residues. Failure of the protein to be carboxylated and/or cleaved results in decreased secretion and intracellular accumulation of proosteocalcin (26). In analogy with its known effect on several cellular enzymes in other systems (for review, see Ref. 36) , AP+ may disrupt the posttranslational modification of osteocalcin by replacing functionally essential metals (such as Mg2+) that are bound to enzymes and small molecules or by binding and modifying irreversibly proteins and nucleic acids. Alterations by AP+ of the chemical composition of membrane phospholipids (37) that are essential for the function of the vitamin K-dependent carboxylase (5) could constitute such a mechanism. Alternatively, A13+ may affect the secretion of osteocalcin in ways similar to its effect on parathyroid hormone secretion, i.e., without interfering with its maturation.
It was shown that in dispersed parathyroid cells A13+ affects the secretion of mature parathyroid hormone, possibly via interference with adenosine 3',5'-cyclic monophosphate production and/or calcium movement between cellular compartments (21). Another theoretical explanation for our findings could be a difference in affinity of the antiserum for the different forms of osteocalcin. Price et al. (29) Notwithstanding this finding, our antiserum may have variable affinity for proosteocalcin and osteocalcin, and therefore our results may reflect the presence of variable amounts of immature forms of the protein.
Our findings suggest a direct posttranscriptional effect of AP+ on osteocalcin synthesis, supporting the observation by others of direct effects of this element on the specialized functions of the osteoblast. Extrapolation from this study to in vivo conditions is difficult because of the intrinsically artifical conditions of our experiment and the transformed nature of ROS 17/2 cells. Nonetheless, our experimental protocol and the in vivo events that result in A13+ toxicity are likely to share some key features: transport of AP+ by transferrin, incorporation of A13+ into cells during active proliferation (when transferrin uptake is highest), and expression of toxic effects of A13+ on the specialized functions of the osteoblast (i.e., osteocalcin metabolism) when cells have reached a matrix maturation-premineralization stage of differentiation and are no longer proliferating. Despite the above limitations, it is tempting to suggest that the dose-dependent pattern of the AP+ effect on ROS 17/2 cells may explain 
